Recently , the domestically produced nine-valent HPV vaccine campus health initiative took a solid step forward at Chongqing University – the first vaccination ceremony of "Wholehearted Protection, Walking with You in Chongqing" was officially launched at Campus A of Chongqing University's Shapingba Campus.

As the second stop in the national university promotion sequence, this event was hosted by the Shapingba District Center for Disease Control and Prevention and organized by Chongqing University Hospital and Xiamen Wantai Canghai Biotechnology Co., Ltd., marking the official launch of China's independently developed nine-valent HPV vaccine, Xinkening 9, in Chongqing , providing more comprehensive, convenient and accessible cervical cancer protection options for women aged 9 to 45 in the city.

This vaccine is China's first and the world's second approved nine-valent HPV vaccine . It received NMPA approval in June 2025, ending the previous reliance on imports for the nine-valent vaccine. Compared to the bivalent vaccine, the nine-valent vaccine protects against more HPV types, including HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. It is suitable for women aged 9-45, with a two-dose regimen for women aged 9-17 and a three-dose regimen for women aged 18-45.

It is worth noting that the price of Xinkening 9 is 529 yuan per dose (including vaccination service fee) , which is about 40% of the price of imported vaccines, significantly improving accessibility to vaccination.

The vaccine was approved based on clinical research data from 11,000 Chinese women, and it can prevent 95.4% of cervical cancers, with a protective effect equivalent to international standards.

A head-to-head study of Cinco-Ning 9 and Gardasil 9 showed that, one month after completing the full course of vaccination in Chinese women aged 18-26 (month 7), Cinco-Ning 9 could induce HPV type-specific immune responses that were non-inferior to Gardasil 9, suggesting that it may have similar protective efficacy to Gardasil 9 .

A recent 3-year follow-up study published in The Lancet Regional Health (Western Pacific) showed that the level of HPV type-specific antibodies induced by Cinco-9 during the immune response plateau phase was comparable to that of Gardasil 9, suggesting that it has similar long-term immune protection potential as Gardasil 9 .

Cervical cancer is a common malignant tumor diagnosed in women worldwide, with approximately 660,000 new cases and 350,000 deaths annually globally. Persistent infection with high-risk human papillomavirus (HPV) is the leading cause of cervical cancer, with HPV types 16/18/31/33/45/52/58 accounting for approximately 95% of invasive cervical cancer (ICC) cases worldwide. HPV vaccination effectively prevents HPV infection and is the most effective long-term intervention to reduce the risk of cervical cancer.

Universities are key areas for HPV prevention and control. The availability of the domestically produced 9-valent HPV vaccine marks a solid step forward in Chongqing's efforts to build a comprehensive prevention and control system. Women aged 9 to 45 can follow the "Chongqing CDC" WeChat service account or consult their nearest community health service center for vaccination.

https://news.yaozh.com/archive/46866.html